Form 8-K ABBOTT LABORATORIES For: Apr 29

May 2, 2022 4:37 PM EDT

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
0000001800 false Common Shares, Without Par Value ABT 0000001800 2022-04-29 2022-04-29 0000001800 us-gaap:CommonStockMember exch:XCHI 2022-04-29 2022-04-29 0000001800 us-gaap:CommonStockMember exch:XNYS 2022-04-29 2022-04-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
   

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

April 29, 2022

Date of Report (Date of earliest event reported)

  

ABBOTT LABORATORIES

(Exact name of registrant as specified in charter)

 

 

 

Illinois   1-2189   36-0698440
(State or other Jurisdiction   (Commission File Number)   (IRS Employer
of Incorporation)       Identification  No.)

 

 

 

100 Abbott Park Road

Abbott Park, Illinois 60064-6400

(Address of principal executive offices)(Zip Code)

 

Registrant’s telephone number, including area code:  (224) 667-6100

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨        Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨        Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨        Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨        Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities Registered Pursuant to Section 12(b) of the Act:

 

Title of Each Class Trading
Symbol(s)

Name of Each Exchange on
 Which Registered

Common Shares, Without Par Value ABT New York Stock Exchange
Chicago Stock Exchange, Inc.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

  

Item 5.07 — Submission of Matters to a Vote of Security Holders.

 

Abbott held its Annual Meeting of Shareholders on April 29, 2022. The following is a summary of the matters voted on at that meeting.

 

(1)The shareholders elected Abbott’s entire Board of Directors. The persons elected to Abbott’s Board of Directors and the number of shares cast for, the number of shares withheld, and the number of broker non-votes, with respect to each of these persons, were as follows:

 

Name  Votes For   Votes Withheld   Broker Non-Votes 
Robert J. Alpern, M.D.   1,300,318,741    50,116,071    186,229,036 
Sally E. Blount, Ph.D.   1,322,633,909    27,800,903    186,229,036 
Robert B. Ford   1,265,246,918    85,187,894    186,229,036 
Paola Gonzalez   1,344,735,483    5,699,329    186,229,036 
Michelle A. Kumbier   1,328,758,586    21,676,226    186,229,036 
Darren W. McDew   1,333,987,306    16,447,506    186,229,036 
Nancy McKinstry   1,037,568,700    312,866,112    186,229,036 
William A. Osborn   1,243,331,162    107,103,650    186,229,036 
Michael F. Roman   1,321,772,019    28,662,793    186,229,036 
Daniel J. Starks   1,343,614,722    6,820,090    186,229,036 
John G. Stratton   1,247,765,004    102,669,808    186,229,036 
Glenn F. Tilton   1,288,825,816    61,608,996    186,229,036 

 

(2)The shareholders ratified the appointment of Ernst & Young LLP as Abbott’s auditors. The number of shares cast in favor of the ratification of Ernst & Young LLP, the number against, the number abstaining, and the number of broker non-votes were as follows:

 

For   Against   Abstain   Broker Non-Votes
1,523,487,443   9,931,288   3,245,117   0

 

 

(3)The shareholders approved the compensation of Abbott’s named executive officers listed in the proxy statement for the Annual Meeting, with 91.27 percent of the votes cast voting “For” the proposal. The shareholder vote is advisory and non-binding. The number of shares cast in favor of approval, the number against, the number abstaining, and the number of broker non-votes were as follows:

 

For   Against   Abstain   Broker Non-Votes
1,232,623,436   110,410,371   7,401,005   186,229,036

 

 

 

 

(4)The shareholders rejected a shareholder proposal to lower the ownership threshold for calling special meetings of shareholders, with 47.15 percent of the votes cast voting “For” the proposal. The number of shares cast in favor of the shareholder proposal, the number against, the number abstaining, and the number of broker non-votes were as follows:

 

For   Against   Abstain   Broker Non-Votes
636,741,987   707,817,833   5,874,992   186,229,036

 

(5)The shareholders rejected a shareholder proposal requesting that Abbott’s Board of Directors adopt a policy that the Board Chairman be an independent director, with 27.75 percent of the votes cast voting “For” the proposal. The number of shares cast in favor of the shareholder proposal, the number against, the number abstaining, and the number of broker non-votes were as follows:

 

For   Against   Abstain   Broker Non-Votes
374,824,445   971,036,526   4,573,841   186,229,036

 

(6)The shareholders rejected a shareholder proposal that Abbott’s Board of Directors adopt a policy on Rule 10b5-1 plans with certain restrictions and disclosure requirements, with 48.76 percent of the votes cast voting “For” the proposal. The number of shares cast in favor of the shareholder proposal, the number against, the number abstaining, and the number of broker non-votes were as follows:

 

For   Against   Abstain   Broker Non-Votes
658,539,820   684,198,068   7,696,924   186,229,036

 

             
(7)The shareholders rejected a shareholder proposal that Abbott’s Board of Directors prepare a report, to be updated annually, disclosing Abbott’s lobbying policies, procedures, and expenditures, with 34.52 percent of the votes cast voting “For” the proposal. The number of shares cast in favor of the shareholder proposal, the number against, the number abstaining, and the number of broker non-votes were as follows:

 

 

For   Against   Abstain   Broker Non-Votes
466,227,363   877,646,614   6,560,835   186,229,036

 

             
(8)The shareholders rejected a shareholder proposal that Abbott’s Board of Directors prepare a report on the public health costs and financial market impacts of Abbott’s standards and programs regarding antimicrobial resistance, with 11.51 percent of the votes cast voting “For” the proposal. The number of shares cast in favor of the shareholder proposal, the number against, the number abstaining, and the number of broker non-votes were as follows:

 

For   Against   Abstain   Broker Non-Votes
155,376,554   1,187,364,353   7,693,905   186,229,036

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ABBOTT LABORATORIES
 
Date: May 2, 2022 By: /s/ Robert E. Funck, Jr.
    Robert E. Funck, Jr.
    Executive Vice President, Finance and Chief Financial Officer

 

 

 

 



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

SEC Filings